

## Information on beta-2 agonists status on the 2010 Prohibited List

The Cyprus Anti-Doping Authority (CyADA) would like to inform athletes, physicians, coaches, and other members of the sport community about the change in the status of certain beta-2 agonists, which are commonly found in asthma medications. This is a follow-up to previous advisory notes concerning the 2010 Prohibited List.

**Salmeterol** and **salbutamol** are no longer prohibited when administered **by inhalation, only**. They require a Declaration of Use, which can be submitted electronically through the CyADA website or using the paper Declaration which can be downloaded from CyADA website and submitted by fax or email.

Salbutamol is still prohibited when administered by any route other than inhalation, e.g., oral (pill form). If salbutamol is detected during drug testing procedures at a level above 1000 ng/mL, the athlete will have the burden of demonstrating through a controlled study that this urinary level was the result of therapeutic inhaled use of this medication.

**All other beta-2 agonists** (e.g., terbutaline and formoterol) **are still prohibited** when administered by any route including inhalation.

Athletes requiring prohibited beta-2 agonists must apply for a Therapeutic Use Exemption (TUE) for asthma, including a complete beta-2 agonist annex and a medical file. Athletes subject to doping control should consult the CyADA website ([www.cyada.org.cy](http://www.cyada.org.cy)) or contact their international federation to get complete information on the application processes.

In addition, athletes selected for doping control must remember to declare the use of all prescribed medications (e.g., asthma medications and glucocorticosteroids) and all non-prescribed medications and supplements taken in the last 7 days.

The following chart lists medicinal products registered in Cyprus containing beta-2 agonists and the process required to use them in sport. Please note that the list below is indicative and is based on the published data from the Pharmaceutical Services, Ministry of Health of Cyprus. Even though every effort to ensure complete and accurate information in this list has been made, the Cyprus Anti-Doping Authority is not responsible for any omissions from the list of the pharmaceutical products containing a substance with  $\beta$ -agonistic action.

**Athletes, at all times, are strongly advised to read carefully the manufacturer's label of the product, and always consult their doctor or pharmacist for proper use. Under no circumstances Athletes shall use drugs provided by third persons or from illegal sources.**

Brand	Ingredient	Route of administration	Requirement	
			TUE	Declaration of Use
<b>BRONCOTEROL INHALATION POWDER IN CAPSULES</b>	Formoterol	Inhalation	✓	
<b>COMBIVENT INHALATION AEROSOL</b>	Salbutamol	Inhalation		✓
<b>FORADIL CAPSULES</b>	Formoterol	Oral	✓	
<b>FOSTER INHALATION SOLUTION</b>	Formoterol	Inhalation	✓	
<b>OXIS TURBUHALER POWDER FOR INHALATION</b>	Formoterol	Inhalation	✓	
<b>SALAMOL CFC-FREE INHALER</b>	Salbutamol	Inhalation		✓
<b>SALAMOL EASI-BREATHE INHALER</b>	Salbutamol	Inhalation		✓
<b>SALBUTAMOL AEROSOL INHALER</b>	Salbutamol	Inhalation		✓
<b>SALBUTAMOL NEBULISER SOLUTION</b>	Salbutamol	Inhalation		✓
<b>SALIPRANEB</b>	Formoterol	Inhalation	✓	
<b>SERETIDE DISKUS</b>	Salmeterol Fluticasone	Inhalation		✓
<b>SEREVENT DISKUS</b>	Salmeterol	Inhalation		✓
<b>SEREVENT EVOHALER PRESSURISED INHALATION</b>	Salmeterol	Inhalation		✓
<b>SPIROPENT SYRUP</b>	Clenbuterol	Oral	✓	
<b>STERI-NEB SALAMOL NEBULIZING SOLUTION FOR INHALATION</b>	Salbutamol	Inhalation		✓
<b>SYMBICORT TURBUHALER</b>	Formoterol Budesonide	Inhalation	✓	
<b>VENTOLIN DISKUS 200MCG</b>	Salbutamol	Inhalation		✓
<b>VENTOLIN EVOHALER AEROSOL</b>	Salbutamol	Inhalation		✓
<b>VENTOLIN SYRUP</b>	Salbutamol	Oral	✓	

The 2010 Prohibited List is available on the website of the Cyprus Anti-Doping Authority ([www.cyada.org.cy](http://www.cyada.org.cy)). For questions on medications you need to use, you may contact CyADA on [info@cyada.org.cy](mailto:info@cyada.org.cy) or by phone +357-22353204. For questions on Therapeutic Use Exemptions or the Declaration of Use process, please contact the CyADA at [tue@cyada.org.cy](mailto:tue@cyada.org.cy) or visit the CyADA website [www.cyada.org.cy](http://www.cyada.org.cy).